Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer

Mothaffar F. Rimawi, Carmine de Angelis, Alejandro Contreras, Fresia Pareja, Felipe C. Geyer, Kathleen A. Burke, Sabrina Herrera, Tao Wang, Ingrid A. Mayer, Andres Forero, Rita Nanda, Matthew P. Goetz, Jenny C. Chang, Ian E. Krop, Antonio C. Wolff, Anne C. Pavlick, Suzanne A.W. Fuqua, Carolina Gutierrez, Susan G. Hilsenbeck, Marilyn M. LiBritta Weigelt, Jorge S. Reis-Filho, C. Kent Osborne, Rachel Schiff

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Fingerprint

Dive into the research topics of 'Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences